Synonym
X 910279; HMR 1279; HMR 279; MNA 279; MNA-279; X91 0279
IUPAC/Chemical Name
Cyclopropanepropanamide, alpha-cyano-N-(4-cyanophenyl)-beta-oxo-
InChi Key
GSSLQBZZKKOMAF-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H11N3O2/c15-7-9-1-5-11(6-2-9)17-14(19)12(8-16)13(18)10-3-4-10/h1-2,5-6,10,12H,3-4H2,(H,17,19)
SMILES Code
O=C(NC1=CC=C(C#N)C=C1)C(C#N)C(C2CC2)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
253.26
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Schorlemmer HU, Bartlett RR, Schleyerbach R. Immunomodulatory activity of malononitrilamides, derivatives of leflunomide's primary metabolite, on models of experimental rheumatoid arthritis. Transplant Proc. 1998 Dec;30(8):4137-9. PubMed PMID: 9865326.
2: Schorlemmer HU, Kurrle R, Schleyerbach R, Bartlett RR. Disease-modifying activity of malononitrilamides, derivatives of leflunomide's active metabolite, on models of rheumatoid arthritis. Inflamm Res. 1999 Dec;48 Suppl 2:S113-4. PubMed PMID: 10667840.
3: Schorlemmer HU, Bartlett RR, Lindner JK, Kurrle R. Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model. Transplant Proc. 1999 Feb-Mar;31(1-2):1184-8. PubMed PMID: 10083529.
4: Slauson SD, Silva HT, Sherwood SW, Morris RE. Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay. Immunol Lett. 1999 Apr 15;67(3):179-83. PubMed PMID: 10369124.
5: Schorlemmer HU, Kurrle R. Combination therapy of malononitrilamides and tacrolimus (FK 506) induced long-term xenograft survival. Transplant Proc. 1998 Dec;30(8):4170-3. PubMed PMID: 9865337.
6: Schorlemmer HU, Kurrle R, Schleyerbach R, Bartlett RR. Generation of O2- radicals in macrophages can be inhibited in vitro and in vivo by derivatives of leflunomide's primary metabolite. Inflamm Res. 1999 Dec;48 Suppl 2:S117-8. PubMed PMID: 10667842.
7: Schorlemmer HU, Bartlett RR, Lindner JK, Kurrle R. Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus. Transplant Proc. 1998 Dec;30(8):4099-103. PubMed PMID: 9865312.
8: Schorlemmer HU, Bartlett RR. Modulation of immunoglobulin dysregulation in graft versus host-and systemic lupus erythematosus-like diseases by malononitrilamides. Transplant Proc. 1998 Dec;30(8):4153-5. PubMed PMID: 9865331.
9: Schorlemmer HU, Bartlett RR, Kurrle R. Malononitrilamides prevent the generation of oxygen radicals in mononuclear phagocytes and graft rejection in a rat model. Transplant Proc. 1999 Feb-Mar;31(1-2):851-3. PubMed PMID: 10083371.
10: Czech J, Kurrle R, Schorlemmer HU. The antiproliferative effect of malononitrilamides (MNAs) on vascular smooth muscle cells is antagonized by exogenous uridine. Inflamm Res. 1999 Dec;48 Suppl 2:S128-9. PubMed PMID: 10667848.
11: Slauson S, Billingham ME, Silva HT, Wang Y, Morris RE. Quilty effect in heterotopic cardiac allografts in malononitrilamide-treated rats. J Heart Lung Transplant. 1999 Dec;18(12):1251-3. PubMed PMID: 10612388.
